TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive Guest Editorial: Myriad Ruling Becomes a Textbook Case Of How Not To Manage a Patent Portfolio, by Robert Cook-Deegan June 14, 2013